- Home
- VRTX vs SNOW Comparison
VRTX vs SNOW Comparison
Compare VRTX & SNOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRTX | SNOW |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer Software: Prepackaged Software |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 41.9B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRTX | SNOW |
|---|---|---|
| Price | $443.80 | $143.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 45 |
| Target Price | ★ $539.69 | $246.45 |
| AVG Volume (30 Days) | 1.2M | ★ 6.7M |
| Earning Date | 05-04-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 15.32 | N/A |
| Revenue | $2,488,652,000.00 | ★ $4,683,946,000.00 |
| Revenue This Year | $10.81 | $28.72 |
| Revenue Next Year | $10.41 | $23.45 |
| P/E Ratio | $28.88 | ★ N/A |
| Revenue Growth | ★ 46.20 | 29.16 |
| 52 Week Low | $362.50 | $118.30 |
| 52 Week High | $510.77 | $280.67 |
Technical Indicators
Market Signals| Indicator | VRTX | SNOW |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 43.01 |
| Support Level | $427.52 | N/A |
| Resistance Level | $467.86 | $157.84 |
| Average True Range (ATR) | 10.89 | 9.25 |
| MACD | 0.73 | -0.97 |
| Stochastic Oscillator | 55.34 | 53.95 |
Price Performance
Historical ComparisonAbout VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About SNOW Snowflake Inc.
Snowflake Inc Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflakes cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The companies data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.